Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma.

Lee, Joycelyn J X; Chan, Jack J; Choo, Su Pin

Lee, Joycelyn J X; Chan, Jack J; Choo, Su Pin.

Afiliação

Lee JJX; Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. joycelyn.lee.j.x@nccs.com.sg.
Chan JJ; Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. jack.chan.j.j@nccs.com.sg.
Choo SP; Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. choo.su.pin@nccs.com.sg.

Diseases ; 3(4): 306-324, 2015 Oct 28.

Article em En | MEDLINE | ID: mdl-28943627

Palavras-chave

c-MET; c-MET inhibitor; cabozantinib; hepatocellular carcinoma (HCC); hepatocyte growth factor (HGF); tivantinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Diseases Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Singapura

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Diseases Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Singapura